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NeocortexSeizures are a prominent symptom in patients with both primary and secondary brain tumors. Medical manage-
ment of seizure control in this patient group is problematic as the mechanisms linking tumorigenesis and
epileptogenesis are poorly understood. It is possible that several mechanisms contribute to tumor-associated
epileptic zone formation. In this review, we discuss key candidates that may be implicated in peritumoral
epileptogenesis and, in so doing, hope to highlight areas for future research. Furthermore, we summarize the
current role of antiepileptic medications in this type of epilepsy and examine the changes in surgical practice
which may lead to improved seizure rates after tumor surgery. Lastly, we speculate on possible future preoper-
ative and intraoperative considerations for improving seizure control after tumor resection.
This article is part of a Special Issue entitled “NEWroscience 2013”.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
Tumor-associated epilepsy (TAE) is a debilitating condition, causing
distress and adversely affecting the quality of life of those suffering from
brain tumors [1–3]. Furthermore, in patients who have had tumor sur-
gery, both the presence of postoperative seizures and the antiepileptic
medication used to treat them have been shown to have a detrimental
neuropsychological effect [2]. In rare cases, TAE can be even more
devastating, giving rise to sudden unexpected death [4]. Despite its
major clinical and social impact, the underlying pathophysiological
causes of TAE are poorly understood, and, as a result, its treatments,
both pharmacological and surgical, are of limited efﬁcacy. Epilepsy
associated with tumors has been shown to have a greater refractivity
to antiepileptic drug treatments, and, in those who have had surgery
for their tumor, seizures may persist postoperatively [5,6].
Seizures can often be the presenting symptom in patients with
brain tumors, whether primary or metastatic and whether intraaxial
or extraaxial [7]. In some cases, seizures occur even before the tumor
is sufﬁciently established to be correctly identiﬁed on computed tomog-
raphy and magnetic resonance imaging [8]. In patients presenting with
other different neurological sequelae, seizuresmay occur after the diag-
nosis has beenmade and, although less likely, even after treatmentwith
surgery or adjuvant therapy [9,10]. The probability that seizures will be
associated with a CNS tumor depends upon the tumor type and gradehe Medical School, Framlington
H, UK. Tel.: +44 191 2088935.
nningham).
. This is an open access article underand its location within the brain or, if extraaxial, its location within
the cranial vault [11].
Themechanism behind TAE is likely to bemultifactorial, and a num-
ber of hypotheses have been proposed. Recent work has explored the
role of changes in peritumoral tissue in seizure generation. This has
revealed metabolic and pH changes, alterations in levels of neurotrans-
mitters and their receptors, and disruption of localized neural networks
in the region of brain tissue surrounding the tumor. This review dis-
cusses the pathophysiology behind TAE, the factors affecting the
frequency and type of the seizures, and the available treatments and
their efﬁcacy.
2. Methods
A literature search was performed in MEDLINE through Web of
Knowledge (Thomson Reuters) searching for publications between
1990 and 2014. Search criteria were the keywords peritumoral + epi-
lepsy. This search yielded 70 results, 9 of which were review articles.
The authors then screened the results and excluded 18 papers that
were not relevant before identifying further salient published work
from the reference lists of the 52 included.
3. Factors governing seizure frequency: tumor type
The frequency and type of seizures associated with TAE depend pre-
dominantly upon the type of tumor giving rise to the seizures and the
location of that tumor within the brain or, in the case of meningiomas,
the location within the skull. All types of primary and secondary brain
tumors may present with seizures [12–14]. Even in those patientsthe CC BY license (http://creativecommons.org/licenses/by/3.0/).
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tential for them to develop TAE in the postoperative period, particularly
those with meningiomas [5,15].
Glioneuronal tumors, primarily arising in children and young adults,
have the highest seizure rate, with 85%–92% of dysembryoplastic
neuroepithelial tumors (DNETs) and 63%–91% of gangliogliomas pre-
senting with seizures [6,7,16–18]. Glioneuronal tumors, as their name
suggests, consist of both dysplastic neurons and neoplastic glial cell ele-
ments [19]. Within the tumor, hyperexcitable regions of dysplastic
neurones develop, and it is thought that this causes their high degree
of epileptogenicity [20].
In tumors of glial origin, low-grade gliomas (WorldHealthOrganiza-
tion (WHO) grades I and II) are more likely to be associated with sei-
zures, with recent studies showing that astrocytomas have a seizure
rate of 50%–81%, and oligodendrogliomas have a seizure rate of between
46% and 78% [7,9,10,21]. These tumors grow slowly, invading the sur-
rounding tissue causing gliosis and chronic inﬂammatory changes
in peritumoral regions. Evidence of these inﬂammatory changes is de-
tectable using immunohistochemical staining; a signiﬁcant increase in
reactive astrocytes is found in cortical peritumoral tissue from patients
with chronic seizures compared with peritumoral tissue from patients
with no seizures [22].
High-grade gliomas such as glioblastoma multiforme (GBM) are
generally thought to be less epileptogenic with a reported seizure rate
of between 22% and 62% although this may be a reﬂection of the shorter
survival time associated with this tumor type rather than a true lower
rate of tumor epileptogenicity; median survival in patients with GBM
is approximately 12 months [5,7,23,24]. Although seizures are less fre-
quent in patients with GBM, they are more difﬁcult to treat, as they
are more often refractory to medication and can persist after surgery
[25]. It is thought that high-grade gliomas give rise to seizures as a
result of localized tissue destruction, ischemia, and necrosis [11,22,26].
Because of their growth rate, high-grade tumors are also likely to effect
epileptogenic changes in the peritumoral region due to mass effect
and as a result of local neuronal network disruption [22]. A hypothesis
previously put forward is that seizure activity may be linked to hemo-
siderin deposition after microhemorrhage from friable tumor vessels
present in high-grade gliomas [1]. Increased levels of extracellular iron
ions (Fe3+) has been shown experimentally to induce paroxysmal epi-
leptiform activity [27]. However, a recent study showed no relationship
between seizure frequency and the presence of hemosiderin on histo-
logical examination of samples from 20 patients with GBM [25].
Meningiomas are among the least epileptogenic intracranial tumors
with a reported seizure rate of between 13% and 26%,whichmay be due
to the fact that they are extraaxial and, therefore, do not inﬁltrate the
brain parenchyma [15,28].
4. Factors governing seizure frequency and semiology:
tumor location
Aside from tumor type, the other most important factor in deter-
mining its epileptogenicity is its location. Studies and reviews vary in
opinion as to whether frontal, temporal, or parietal lobe tumors are
most likely to be associated with seizures, but most agree that occipital
lobe lesions are the least epileptogenic [7,11,22,29–32]. In their review
of 2342 patients with TAE from mixed tumor types, Hamasaki et al. re-
ported a frontal predominance in tumor location, speciﬁcally in cortical
regions close to themotor cortex [7]. Michelucci et al. reviewed 100 pa-
tients with seizures related to primary brain tumors and found that 60%
were located in the frontal lobe, with temporal and then parietal lobes
as the next most common locations [31]. When tumors are grouped
by type, different tumor histology is more likely to be related to speciﬁc
brain regions. Glioneuronal tumors are most commonly located in
the temporal lobe and cause predominantly complex partial seizures
[6,19,33]. High-grade gliomas are most likely to involve multiple brain
regions but, when conﬁned to single lobes, are found most commonlyin the temporal and frontal lobes [34]. High-grade gliomas made up
the majority (79%) of a review of patients with primary brain tumors
in whom the initial seizures were predominantly tonic–clonic or focal
motor [31]. Location is also a factor in the propensity of meningiomas
to cause seizures: convexity and parasagittal/parafalcine meningiomas
close to the premotor cortex are associated with the greatest seizure
rates (28%–40%), with tuberculum sella meningiomas being the least
epileptogenic [15,28,35].
It may be that tumors in the anterior frontal lobe are in fact as likely
to cause epileptic activity as tumors in the posterior frontal lobe and
temporal lobe, but that the relative lack of eloquence of the frontal
regions means that some of these seizures go undetected. Although
less likely, tumors in the occipital lobe can also produce seizure activity,
typically producing visual auras before a seizure [7,36]. Sellar and skull
base tumors, including pituitary tumors and craniopharyngiomas,
seem to be much less likely to present with seizures, with Deepak
et al. showing a seizure rate of only 9% in their series of 64 patients
with macroprolactinomas and Karavitaki et al. ﬁnding no seizure ac-
tivity in a case series of 121 patients with craniopharyngioma [37,38].
5. Pathophysiology
The pathophysiological mechanisms that give rise to epileptic activ-
ity in brain tumors are likely to bemultifactorial. The literature describes
a number of hypotheses relating to the biochemical, microstructural,
and electrical environment of the peritumoral area that may give rise
to epileptogenesis [1,14,26,29,33,39–42]. These include the levels of
neurotransmitters and altered expression of their receptors, altered ex-
pression of gap junctions and ion channels, localized pH disturbance,
and the effects of disruption of the blood–brain barrier [43–47].
There is evidence to show that different mechanisms predomi-
nate in different tumor types. In tumors containing neurons such as
glioneuronal tumors, disruption of neuronal function is the most likely
mechanism, whether through the development of hyperexcitable
regions of dysplastic neurones within the tumor or neuronal immuno-
reactivity to certain gap junction proteins (see below) [20,43,48].
Both of these factors are likely to contribute to the high degree of
epileptogenicity displayed by this tumor type, but other mechanisms
must be responsible for tumors of exclusively glial origin, with no neu-
ronal component. Recent evidence suggests that slow growing tumors
may induce changes in penumbral connectivity, resulting in the devel-
opment of network architecture with suboptimal functionality and
a lower threshold for seizures [49]. In contrast, higher-grade tumors
may induce seizures by tissue damage (ischemia, edema, mass effect,
and necrosis) [40].
6. Neurotransmitters and receptors in the peritumoral zone
Alterations in glutamate neurotransmission form a core part of the
pathophysiology of epileptogenesis. This is not surprising given the
excitatory nature of this neurotransmitter in the brain and, thus, its
depolarizing action on the neuronal membrane potential [50]. The elec-
trical excitability of tumor cells in gliomas was established in vitro in
1996 [51]. Previously, it had been thought that tumors arising from
glial cells, unlike those from neurones, lacked the Na+ channels that
allow a membrane potential to be generated. However, Patt et al. dis-
covered that a large number of cells in gliomas expressed Na+ channels
in sufﬁcient quantities to allow generation of brief bursts of action po-
tentials. Activation of glutamate (AMPA/kainate) receptors in glial
tumor cell membranes caused this depolarization both in ex vivo
human tumor brain slices and cultured human tumor material. These
ﬁndings indicate that glioma cells may have electrophysiological prop-
erties similar to those of neurons [44]. However, evidence to support
that these glia with neuron-like properties exert an epileptogenic effect
is not presently available. Indeed, it is unlikely that this is the case
given that the seizure foci are more often than not found within the
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a lack of correlation of glial Na+ current density and its position relative
to the seizure foci supports this notion [52].
Aside from intrinsic changes in glial cell behavior, these cells are also
known to exert amuchwider inﬂuence on neuronal networks, and they
achieve this in a variety of ways. Astrocytes have been shown to be ca-
pable of the release, reuptake, and synthesis of neurotransmitters; the
provision of neurotransmitter precursors and lactate; the regulation
of pH; and the regulation of extracellular K+ concentration. Because of
the excitatory nature of glutamate, early studies focused on the role of
extracellular glutamate in the generation of tumor-associated epilepsy.
These ﬁndings have not been particularly robust. Bateman et al. demon-
strated similar levels of glutamate both in human samples obtained
from patients with tumor-associated seizures and patients with tumors
who did not display seizures [53]. This study did observe increased glu-
tamine in glioma samples associatedwith epilepsy.More recently, using
microdialysis techniques in patients with high-grade gliomas, we have
reported that glutamate is found in higher concentrations in the
tumor margin as compared with peritumoral regions [54]. However, it
has also been demonstrated that extracellular glutamate is signiﬁcantly
decreased in the peritumoral region of high-grade gliomas [55]. An in-
crease in extracellular glutamate is supported by a study performed
by Rosati et al. in 2009. They demonstrated that levels of glutamine
synthetase (an enzyme that protects neurons against excitotoxicity by
facilitating glutamate uptake and conversion to glutamine) were signif-
icantly lower in patients with GBM and epilepsy than in those with
nonepileptic GBM [25]. Work by Yuen et al. also implicates glutamate
in epileptogenesis; they analyzed a retrospective patient group with
samples stored after surgery and a prospective cohort in whom glioma
tumoral and peritumoral samples were subsequently taken and found
an increased concentration of glutamate in tumor and peritumor
which showed a signiﬁcant correlation with the presence of seizures
[56]. They also discovered that expression of the transporter protein
system xc−was increased in peritumoral tissue andwas an independent
predictor of the presence of tumor-associated epilepsy. More recently,
Buckingham et al. have demonstrated, using in vitro electrophysiology,
signiﬁcant glutamate release in amousemodel inwhich human derived
glial tumors were implanted. Furthermore, this group has shown that
the resultant epileptiform activity spreads fromglial tumor cells into ad-
jacent brain tissue [57]. The same group has subsequently shown a re-
duction in the duration of peritumoral epileptiform discharges after
the suppression of glutamate release by blocking the transporter pro-
tein system xc−with sulfasalazine and has concluded that increased ex-
tracellular glutamate is, therefore, a causative factor in peritumoral
cortical synaptic network hyperexcitability [58]. However, a degree of
care should be taken with respect to these ﬁndings. Firstly, the authors
did not observe spontaneous epileptic activity in peritumoral slices and
resorted to the use of the zeromagnesium technique to induce epileptic
activity in the brain slices obtained from the mouse tumor model.
Secondly, while sulfasalazine reduced the duration of interictal epilepti-
form discharges, it also, paradoxically, increased the rate of these
events. Finally, robust concentrations (250 μM) of sulfasalazine failed
to completely block the epileptic discharges (measured both at the sin-
gle neuron and network level) induced by zero magnesium containing
artiﬁcial cerebrospinal ﬂuid. Moreover, preliminary data from our own
work (Cowie and Cunningham, unpublished observations) suggest
that much lower concentrations of sulfasalazine (10–20 μM) can
completely abolish spontaneous epileptic discharges in human
peritumoral slices maintained ex vivo.
In contrast to glutamate, gamma-aminobutyric acid (GABA) is an
inhibitory neurotransmitter in the brain and, as such, acts as a coun-
terbalance to excitation. An asymmetry of enhanced excitation and
disrupted inhibition has been postulated in a number of epileptic condi-
tions. However, this view has been complicated by recent ﬁndings in
which depolarizing GABA has been described in epileptic human tissue
[59,60]. Thus, for human focal epilepsies, alterations in chloridehomeostasis can switch GABA neurotransmission from hyperpolarizing
to depolarizing and, therefore, decrease the threshold for seizure genesis.
In addition to this ﬁnding, a suppression or loss of GABA-mediated inhi-
bition has also been implicated in the pathophysiology of epilepsy, in-
cluding in peritumoral epilepsy. Using human neurosurgical samples
removed from temporal lobe low-grade gliomas, a reduction in somato-
statin andGABA immunoreactive neurons has been observed in epileptic
peritumoral regions (assessedwith intraoperative electrocorticography)
as compared with nonepileptic areas surrounding the tumor [61]. Fur-
thermore, a single patient study of the peritumoral neocortex from
a temporal lobe astrocytoma revealed a reduction in parvalbumin im-
munoreactivity and inhibitory synapses at the perisomata and axonal
initial segment of pyramidal cells [62]. From a functional perspective,
GABA-evoked currents in oocytes injected with membranes obtained
from human epileptic peritumoral cerebral cortex show a more
depolarized reversal potential when compared with those obtained
from nonepileptic healthy cortex, and this difference is attributed to in-
creased expression of two Cl− ion membrane transporters (NKCC1 and
KCC2) in neurons in the peritumoral neocortex [63]. This increase
in neuronal Cl− transporters will, as in the case of focal epilepsies
[59,60], ensure that GABA acts to depolarize rather than hyperpolarize
pyramidal neurons, thereby contributing to epileptogenesis in human
brain tumors. Scant evidence exists for concentrations of GABA in
peritumoral regions. One study has demonstrated increased GABA in
the peritumoral zone of glioblastomas but no similar increase of the in-
hibitory neurotransmitter in regions surrounding anaplastic astrocyto-
mas and oligodendrogliomas [55].
In addition, functional GABA receptors have been identiﬁed on glio-
ma cells themselves. Labrakakis et al. showed the presence of GABAA
receptors on WHO grade II and III cells from low-grade gliomas and
anaplastic astrocytomas, which, in the majority of their experiments,
caused depolarization and not hyperpolarization of the glioma cells
[45]. Interestingly, the authors demonstrated that application of GABA
triggered the activation of voltage-gated Ca++ channels and, therefore,
hypothesized that the observed depolarization was linked to Ca++ in-
ﬂux into the cells. They also showed that these functional GABA recep-
tors were not found in glioblastoma cells, allowing their presence
to be used as a marker to differentiate between the tumor types. This
ﬁnding ﬁts with the known increased epileptogenicity of low-grade
gliomas when compared with GBM [7].
Control of extracellular ionic homeostasis is also critical in the gene-
sis of seizures [64]. Central to this is the ability to regulate concentra-
tions of extracellular potassium (K+). Extracellular K+ homeostasis is
conducted by astrocytes by buffering via the Kir4.1 channel. Polymor-
phisms or mutations of murine and human KCNJ10, which encodes
the astroglial Kir4.1 K+ channel, are associated with epilepsy [65]. Fur-
thermore, the ability for potassium buffering is impaired in gliomas
through a reduction in the expression of Kir4.1 in the plasmamembrane
of glioma cells [66]. However, at present, no direct evidence exists to
demonstrate alterations of Kir4.1 in the peritumoral region and if any
change might directly contribute to epileptogenesis in these zones.
7. Alterations in pH in the peritumoral zone
In addition to changes in the balance of neurotransmitters, alter-
ations in peritumoral zone pH have also been put forward as a hy-
pothesis for increased epileptogenicity. In general, alkalosis increases
membrane excitability, often to an epileptogenic level, while acidosis
decreases membrane excitability [67]. However, this is not always the
case, and it seemsmore likely that it is the pH shift in the tumor micro-
environment, rather than the absolute pH, which is responsible for the
effects on the function of neurotransmitter receptors, gap junctions,
and ion channels involved in altering cellular excitability [47]. Using
MR spectroscopy, it has been shown that gliomas have a highly acidic
extracellular pH, while, conversely, their intracellular pH is alkaline
[68–70]. One hypothesis to explain the underlying mechanism behind
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calized hypoxia [32]. Tumors display a disorganized vasculature, which
results in unbalanced perfusion, and are dependant on an adequate
blood supply for growth. As gliomas increase in size, they can outgrow
their vascular supply and, hence, develop areas of hypoxia [71]. This is
particularly true of high-grade gliomas where hypoxia and ischemia
can lead to necrosis, a ﬁnding often observed at surgery and later on
in histology. It is known that in the presence of hypoxia, cellularmetab-
olism favors glucose catabolism and results in lactic acid production.
The subsequent acidosis leads to glial cell swelling and damage and it
is possible that this may lead to increased seizure generation [32,72].
In lower grade tumors, localized acidity causes astrocytoma cells and
malignant glial cells to demonstrate an increased Na+ inﬂux and may
lead to increased cellular excitability [71,73].
However, if thiswere the onlymechanism coupling changes in pH to
epileptogenicity, then it ought to be the case that the high-grade tumors
most susceptible to hypoxia and ischemia would be thosemost likely to
exhibit seizures, and this is clearly not the case. Therefore, it is likely that
if themechanismdescribed above does play a role, then it is contributed
to and modiﬁed by other pH-mediated pathophysiology.
Another hypothesis linking pH to epileptogenesis involves the in-
creased expression of carbonic anhydrase (CA) IX in gliomas. Carbonic
anhydrase (CA) is the enzyme that catalyzes the reaction CO2 + H2O
to HCO3−+ H+, and its action is upregulated in hypoxia [47]. Carbonic
anhydrase IX is unusual when compared with other forms of CA as it
spans the cellular membrane and its reaction products are separated:
H+ is moved out of the cell and HCO3− is moved back into the cell cyto-
plasm. Proescholdt et al. have shown that CA IX was overexpressed in
every one of 59 glioblastoma samples they analyzed and also found
that it was an independent prognostic factor for poor outcome [70].
Thismay be themechanism bywhich the peritumoral extracellular ma-
trix is kept acidotic and the intracellular environment alkalotic, and
doing so is likely to increase the excitability of the peritumoral network.
One way in which this may occur is via gap junctions (see below). The
pH sensor of these channels has been suggested to be located on the
cytoplasmic side of the pore [74], thus an intracellular alkalinization
will lead to opening of these channels with implications for neuronal
and glial network connectivity.
8. Gap junction-mediated connectivity
Gap junctions (GJs) are a means of intercellular communication and
consist of membrane proteins (connexins) that form a channel from the
membrane of one cell to themembrane of a neighboring cell. They allow
the transfer of small metabolites (amino acids, glucose, glutathione, and
ATP), small signalingmolecules, andmicroRNAs [75,76], they are sensi-
tive to changes in pH and Ca++ concentrations, and they permit the
movement of ions from one cell to the other. Thus, GJs can act as a pow-
erful means of synchronizing network behavior either via direct electri-
cal signaling in neurons or by the propagation of glial Ca++ waves. In
both instances, increased GJ communication will lead to increases in
excitability and a hypersynchronous state. A large body of work has fo-
cused on the implications of GJ connectivity between neurons in the
hippocampus and neocortex. Gap junction-mediated direct electrical
coupling between pyramidal cells [77–80] and GABAergic interneurons
[81–86] in these regions has beenwell documented. The dendritic local-
ization of GJ coupling between interneurons [87–90] has been shown to
be important for physiological [91–93] and pathophysiological [94,95]
neuronal rhythmogenesis. In contrast, there remains a degree of contro-
versy surrounding the precise location of GJ coupling between pyrami-
dal neurons. Schmitz et al. have provided confocal imaging evidence of
apposition of CA1 pyramidal cell axons that permits themovement of a
ﬂuorescent dye from one neuron to another [96]. In addition, this study
also provided physiological evidence in the formof spikelets recorded in
CA1 pyramidal cells in the absence of chemical synaptic transmission
and in response to CA1 axon collateral stimulation. Furthermore,connexin (Cx) 36 expressing GJs between hippocampal mossy ﬁbers
has been demonstrated using a combination of transmission electron
microscopy and freeze fracture immune-gold replica labeling [97].
In epileptic human neocortex, a network or ‘plexus’ of GJ-coupled
pyramidal cell axons has been demonstrated to underlie the generation
of high frequency oscillations (HFOs) [98–100]. High frequency oscilla-
tions are implicated in the epileptogenic process and are emerging as a
useful clinical tool in terms of seizure focus delineation [101–103]. Nu-
merous studies have used either preoperative electroencephalography
(EEG) or intraoperative electrocorticography (ECoG) for the functional
resection of gliomas in order to gain seizure freedom [24,104]. At
present, it remains unclear if functional resection produces a clear de-
gree of seizure control in patients with TAE (see below). The reasons
for this are likely to be multifactorial. However, given the speciﬁcity of
HFOs to locate seizure-onset zone in intractable focal epilepsy [105], it
may be reasonable to propose that a similar temporal high resolution
approach should be implemented in surgical treatment. Evidence of
HFOs has emerged from one study in which intracranial subdural
grids have been used. The patient presented with a right temporal
oligodendroglioma and intractable epilepsy, and HFOs coincident with
ictal slow direct current (DC) shifts were observed in the peritumoral
neocortex [106]. Ex vivo studies conducted in the laboratory of one of
the authors have observed the occurrence of spontaneous HFOs associ-
ated with interictal discharges in peritumoral tissue obtained from
patients undergoing elective neurosurgery for the treatment of TAE
(Cunningham et al., unpublished observations). Previous ﬁndings
from this laboratory have supported the role of axoaxonic gap junction
coupling in the generation of HFOs in epileptic tissue obtained from pa-
tients with temporal lobe epilepsy [98–100]. The existence of axoaxonic
gap junction coupling in epileptic peritumoral tissue still needs to be
tested, but the presence of changes in gap junction coupling between
glial cells has been well documented.
Two types of gap junction proteins expressed in glial cells have been
studied in relation to peritumoral epilepsy: connexin 32 (Cx32), which
is known to be expressed in oligodendrocytes, and connexin 43 (Cx43),
the predominant gap junction protein in astrocytes. An early study com-
pared cortical tissue samples from patients undergoing resection for
epilepsy, with peritumoral cortical tissue both from patients who had
TAE and thosewhohad no seizures [107]. The authors showed an eleva-
tion in mRNA coding for the gap junction protein Cx43 both in the
patients with intractable epilepsy and in the patients with tumor with
seizures and lower levels of the same protein in patients with tumor
with no associated seizures. A more recent study by Aronica et al. has
demonstrated strong labeling of the Cx32 gap junction protein in
glioneuronal tumors (both gangliogliomas andDNETs) and also showed
increased expression of the Cx43 gap junction protein in reactive
astrocytes in epileptic peritumoral cortex undergoing gliosis in patients
with low-grade gliomas [43]. They suggest that the greater expression
of these gap junction proteins, speciﬁcally in peritumoral astrocytes
and in low-grade tumors known to be highly epileptogenic, may
mean that they are implicated in synchronization (via astrocytic Ca++
elevation) of localized peritumoral neural networks, leading to propa-
gation of seizure activity [108].
9. Blood–brain barrier
The blood–brain barrier (BBB) is the means by which the brain cells
and their extracellular ﬂuid are kept apart from the blood and protected
from harmful molecules within it. It is a function of occluding junctions
between capillary epithelial cells, astrocytes, and pericytes and is
unique to the capillaries in the central nervous system [32]. Brain tu-
mors are known to cause disruption to the BBB resulting in edema
and leaking of microscopic particles and large molecules into the
peritumoral region, such as glutamate and albumin, both of which are
known to cause seizures [46,109]. In 2004, Seiffert et al. demonstrated
that disruption of the BBB caused foci of epileptiform discharges in
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neuronal functional impairment following the development of the epi-
leptic focus as a result of BBB disruption [111]. Interestingly, in 2008,
Savaskan et al. showed that system xc−, the glutamate transporter pro-
tein overexpressed in gliomas and possibly already implicated in
tumor-associated epilepsy (see above), has been shown to be involved
in disruption of the blood–brain barrier; animals implanted with
a type of system xc− with a silenced active subunit had signiﬁcantly
less peritumoral edema compared with animals with normal system
xc− [112]. The BBB also plays a role in maintaining pH homeostasis
through its acid–base transporter molecules, and disruption of the BBB
has been shown to increase extracellular pH within the brain [47,113].
As discussed above, shifts in pH are associated with increased seizure
activity, and this mechanism may further implicate BBB disruption in
epileptogenesis in the peritumoral zone.
10. Treatment of tumor-associated epilepsy
The natural course of epilepsy associated with brain tumors differs
from that of epilepsy from other causes. In part this is due to the fact
that, in a large number of cases, the patient will undergo surgery for
diagnostic, debulking, or curative purposes, and the surgery itself may
act to cure the epilepsy. The patientmay also undergo adjuvant therapy
which can affect seizure frequency or, in the case of chemotherapy,
may interact with antiepileptic medication [114]. Most patients with
tumor presenting with seizures will be started on an antiepileptic
drug (AED), which may be weaned after surgery in the absence of
postoperative seizures.
It was previously thought that TAE responded very poorly to anti-
epileptic medication, but recent studies have demonstrated more
encouraging rates of seizure control with newer AEDs [115–118].
However, in a large number of cases, epilepsy associated with brain tu-
mors can be difﬁcult to manage. Patients with seizures refractory to
pharmacological treatment often end up on multiple AED regimes,
and those who undergo surgery may be left with seizures postopera-
tively and still require AEDs [9,119]. As discussed above, the initial
presenting symptom in patients with tumor is often seizures, and
they may be started on an AED before a diagnosis is made. Interesting-
ly, as the focus of initial treatment is primarily neurooncological, it is
possible that patients with TAE may not be treated by an epileptologist
but rather have AEDs started by their emergency physician, neurosur-
geon, or neurooncologist. While this management may be adequate,
TAE is known to be difﬁcult to control, and, therefore, it would seem
most sensible for them to be referred to an epilepsy specialist early
in their treatment.
11. AEDs
In patients with brain tumor presenting without seizures, the ques-
tion of whether to initiate prophylactic AEDs had previously been based
only on an outdated review of the use of prophylactic AEDs in traumatic
brain injury [42]. In 2006, a review of the existing literature on the sub-
ject was conducted by Perry et al. revealing only a handful of random-
ized controlled trials, a review, and a single published guideline [120].
The conclusion of their review was that there was no evidence
supporting the use of prophylactic AEDs in patients with tumor, as
there is no difference in the risk of having a seizure between patients
with tumor taking AEDs and those not doing so [121–123]. Interesting-
ly, a general review of epilepsy in brain tumors in 2010 suggests that
as some newer AEDs have an improved safety proﬁle compared with
older AEDs, they should now be considered for prophylaxis in patients
undergoing craniectomy (presumably craniotomy) for tumor, but that
they should be stopped oneweek postoperatively [42]. The same review
also states that, in cases where prophylactic AEDs are not given,
they should be initiated after only one seizure and that doing so hasbeen shown to reduce the rate of seizure conversion from focal to
generalized [124].
Antiepileptic drugs are typically classed into three groups: ﬁrst-
generation drugs, e.g., sodium valproate, phenytoin, carbamazepine,
and benzodiazepines; second-generation drugs, e.g., levetiracetam, gaba-
pentin, lamotrigine, and oxcarbazepine; and the newest third-generation
drugs, e.g., pregabalin, brivaracetam, and lacosamide [125,126].
Most AEDs affect neurotransmission by modulating voltage-gated
sodium, calcium, or potassium ion channels and/or by action on GABA
receptors or by altering GABA concentration, thereby increasing the in-
hibitory action it has on action potential propagation [127]. A small
number of AEDs instead alter glutamate receptors, causing restriction
of excitatory neurotransmission.
A recent very thorough review by de Groot et al. lists the studies,
both retrospective and prospective, which assess the efﬁcacy of differ-
ent AEDs speciﬁcally in tumor-related epilepsy [40]. All three genera-
tions of AEDs have been studied in TAE, but the majority of work
has involved more recent drugs such as levetiracetam, topiramate, and
gabapentin and has demonstrated rates of seizure freedomwith mono-
therapy at between 20% and 55%, irrespective of the agent studied
[128–130]. However, a retrospective analysis of pediatric patients with
TAE showed that those started on second-generation AEDs were less
likely to have had to change to a different drug compared with those
started on ﬁrst-generation agents [131]. While the results of all these
studies indicate that most AEDs are able to control TAE in up to half
the numbers of cases, the published works have suffered from low
patient numbers, with the largest group studied numbering only 47 pa-
tients [128].
There have also been a small number of papers comparing the use of
older AEDswith newer ones,with authors comparing levetiracetamand
oxcarbazepinewith phenytoin, sodium valproate, and other older AEDs
[40,117,119,132]. The results of these predominantly retrospective
studies have shown little difference in seizure reduction or freedom be-
tween ﬁrst-generation and second-generation AEDs, but some do show
that the newer drugs give rise to fewer side effects [132]. Although it
would seem from the research comparing the different types of AEDs
that no one drug affords better seizure control, there are drugs which
are preferable in TAE due to their reduced effect on the hepatic enzyme
cytochrome P450 (CYP) [133]. Older drugs, such as carbamazepine,
phenytoin, phenobarbital, and sodium valproate have been found to
be either inducers or, in the latter's case, inhibitors of CYP, and this
may have implications for patients with tumor having chemotherapy,
as some cytotoxic drugs are known to be metabolized by this enzyme
[114,134]. Conversely, it is known that some chemotherapeutic agents
are themselves inducers or inhibitors of CYP [135]. Therefore, when pa-
tients are treated concurrentlywith older AEDs and cytotoxic drug ther-
apy, an increase or decrease in plasma concentration of the anticancer
drug or AED could occur, resulting in toxicity (with either drug type)
or in inadequate chemotherapeutic coverage or loss of seizure control.
Interestingly, a review in 2010 by Rossetti and Stupp comments on
data from an analysis of the European Organisation for Research and
Treatment of Cancer database [42]. It shows that patients with tumor
on newer AEDs that do not induce CYP, such as gabapentin, levetirace-
tam and pregabalin, have a better outcome from chemotherapy. There-
fore, AED selection must be considered carefully in patients with TAE
who are to undergo chemotherapy to avoid drug interactions and to op-
timize outcome.
12. Surgery
The majority of patients with TAE will undergo surgery at some
point in their treatment. Over recent years, particularly in low-grade
gliomas, the surgical trend has been to move away from biopsies
or limited resections towards maximal safe resection, with evidence
showing that this more aggressive approach is associated with better
prognosis [48]. Tumor excision has been found to have varying success
58 C.J.A. Cowie, M.O. Cunningham / Epilepsy & Behavior 38 (2014) 53–61in the treatment of TAE, with outcomedependent on tumor type, on the
severity and frequency of preoperative seizures, and on the degree
of surgical resection. This question of surgical resection is possibly the
most important factor in tackling TAE, as it is the one factor that can
be altered. It seems that the most likely reason for partial resection
resulting in poorer control of TAE postoperatively is that the epilepto-
genic focus has not been removed. It is, therefore, not surprising given
the recent move to safely resect more tissue to see that postoperative
seizure rates have improved towards the end of the last decade. A retro-
spective analysis published in 2001 looking only at postsurgical seizure
outcome in 45 glioneuronal tumors found that only 63% of patientswith
gangliogliomas and 58% of thosewith DNETs were seizure-free after re-
section [6]. The authors found that young age, total resection, absence of
generalized seizures, and shorter duration of epilepsy were predictors
of better postsurgical seizure outcome. In 2003, Klein et al. found that
50% of 156 patients with low-grade tumors demonstrated seizures
after resective surgery [2]. Hildebrand et al. published their ﬁndings
in 2005 on 234 patients with gliomas and found that almost 80% expe-
rienced tumor-related epilepsy after surgery, although their paper does
not state whether the patients simply had biopsies performed for histo-
logical diagnosis or whether they had resections or debulking surgeries
instead [124]. More recent results have been more encouraging; Babini
et al. published the results of their study in 2013 where they compared
postoperative seizure rate in children between one group who
underwent simple resection for their low-grade glioma and another
group who underwent tumor resection along with resection of the sur-
rounding epileptogenic peritumoral zone deﬁned preoperatively using
EEG [136]. The seizure-free rate was 80% in those who underwent
straightforward resection and 100% in those in whom the resection
was extended to include the peritumoral region. Chaichana et al. per-
formed a similar retrospective analysis in 2009 looking at 153 patients
operated upon for GBM or anaplastic astrocytoma and found that
77% were seizure-free at 12 months, with lower grade and temporal
and/or cortical location as predictors of increased postoperative seizure
activity [137]. The same authors performed a further retrospective
analysis in 2013, this time looking at seizure outcome aftermeningioma
resection [28]. Of their 84 patients with preoperative seizures, 90%were
seizure-free after tumor removal, and they found that the presence of
uncontrolled preoperative seizures along with a tumor located on the
sphenoidwing or in the parasellar regionwas an independent predictor
of poorer postoperative seizure control.
Neurosurgery for tumor excisionwhere a cure cannot be affected is a
balance; in high-grade tumors a greater extent of resection increases
time to tumor progression and median survival, and a similar trend
suggests that the same may be true of low-grade gliomas [138,139].
However, the need to remove asmuch tumor as possible must be coun-
tered by the desire to increase quality survival and not increased surviv-
al at any cost. This aim is achieved at surgery by preserving as much
normal brain parenchyma as possible, and the more eloquent the
brain area, themore cautious and limited the tumor resection. This con-
servative approach increases the likelihood that patients suffer from
fewer permanent neurological deﬁcits postoperatively but may be im-
plicated in poor postoperative seizure control, especially if resection
spares an epileptogenic focus located in the peritumoral region.
Where the quality of survival is themain concern, the impact of seizures
and the side effect of AEDs must also be considered alongside the need
to preserve neurological function.
13. Future directions for improved seizure outcome
Asmentioned above, there has been a trend in neurooncological sur-
gery towards maximal safe resection. Surgical technology has played a
signiﬁcant part in the safety of this observed increase in the extent of
tumor resection and subsequent improvement in postoperative TAE
rates. There have been advances in image guidance (both CT and MR),
and these have also beneﬁtted from the ability to combine standardanatomical images with information gleaned from functional and
diffusion-weighted advanced MR sequences [140,141]. Initial research
on ﬂuorescein-assisted glioma surgery has also shown an increase in
the ability to achieve gross total resection over partial resection [142].
The logical next step in glioma surgery must be to enhance resection
further not only to improve prognosis but also to improve quality
of life by reducing postoperative seizure rates. As more is learned
about the neurobiological alterations that occur in the peritumoral
zone and their impact on epileptogenesis, it seems more likely that re-
moval of this border of tissue around brain tumors may improve the
outcome from TAE. There is already an armamentarium of tests used
to locate epileptic foci in surgery for nontumoral epilepsy. These
include, but are not limited to, preoperative investigations (EEG, PET
scanning, and MR spectroscopy) and intraoperative electrocorticogra-
phy. Using these techniques, a greater insight into the clinical reliabil-
ity of a biomarker or a combination of biomarkers (neurotransmitter
levels (glutamate, GABA), HFOs, pH) in relation to the peritumoral
zone and postsurgical outcomes can be assessed. It seems reasonable
to investigate how these modalities and potential biomarker signals
obtained with such measurements could be linked to existing image
guidance systems to allow increasingly accurate and safe resection
of peritumoral tissue for a radical improvement of seizure outcome
in TAE.
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